

#### **Abstract**

## **Objective:**

- Preterm infants born small, vs. appropriate for gestational age (SGA, AGA) are at greater risk
- for morbidity and mortality. The contribution of genetic disorders to preterm SGA birth,
- morbidity, and mortality is unknown. We sought to determine the association between genetic
- disorders and preterm SGA birth, and the association between genetic disorders and morbidity
- or mortality within preterm SGA infants. We hypothesized that genetic disorders were
- significantly associated with both.

## **Study Design:**

- This was a retrospective multicenter cohort study of 409 339 infants, born 23–33 weeks'
- gestation between 2000 and 2020. The odds of preterm SGA (vs AGA) birth, and the odds of
- severe morbidity or mortality within SGA preterm infants were determined for infants with

genetic disorders, after adjusting for known risk factors.

### **Results:**

- Genetic disorders were present in 3.0 and 1.3% of SGA and AGA preterm infants respectively;
- genetic disorders conferred an aOR (95% CI) of 2.06 (1.92, 2.21) of SGA birth. Genetic
- disorders were present in 4.3 of preterm SGA infants with morbidity or mortality and 2.1% of
- preterm SGA infants that did not experience morbidity or mortality. Genetic disorders conferred

an aOR (95% CI) of 2.12 (2.66, 3.08) of morbidity or mortality.

#### **Conclusions:**

- Genetic disorders are strongly associated with preterm SGA birth, morbidity, and mortality.
- Clinicians should consider genetic testing of preterm SGA infants, particularly in the setting of
- other comorbidities or anomalies. Prospective, genomic research is needed to clarify the
- contribution of genetic disorders to disease in this population.
- 
- 

53

## 54 **Introduction**

55 Preterm infants experience a profound burden of morbidity and mortality, and small for 56 gestational age (SGA) birth is one of the strongest clinical risk factors for poor outcomes. <sup>1-9</sup> 57 SGA is defined as birth weight less than the  $10<sup>th</sup>$  percentile or two standard deviations below 58 mean for gestational age and sex based on estimates of population distributions.<sup>10-13</sup> The 59 mechanism(s) by which SGA birth confers clinical risk are largely unknown. Known factors 60 including impaired metabolic reserve explain only a fraction of these outcomes.<sup>14</sup> Although there 61 are known risks for SGA birth, including maternal, placental, infectious, genetic, and 62 environmental factors, the etiology of SGA birth is poorly understood. Known risks include 63 maternal.<sup>14-16</sup>

64

65 The overall contribution of genetic disorders to preterm SGA birth is unknown. Fetal growth 66 restriction (FGR) and continued poor fetal growth often impacts the decision to prematurely 67 deliver a fetus. Multiple studies have found genetic disorders associated with FGR. $^{17,18}$  Higher 68 rates of aneuploidy and copy number variants are found in FGR, particularly when presenting 69 before 32 weeks' gestation or accompanied by other fetal anomalies.<sup>19,20</sup> Metanalysis of exome 70 and genome sequencing for FGR demonstrated single gene disorders in 4% of isolated FGR 71 and 30% of FGR accompanied by other anomalies.<sup>17</sup> Genetic disorders have been shown to 72 contribute to morbidity and severe mortality in related populations as well. Genetic disorders 73 have been found in 6% of stillbirths, 10% of fetal structural anomalies, and in 20% of cohorts of 74 pediatric critical illness or perinatal disease. $21-26$ 

75

76 Given the burden of illness experienced by preterm SGA infants, emerging evidence that 77 genetic disorders cause FGR and SGA, and evidence that genetic disorders cause critical 78 illness in related populations, we sought to determine the contribution of commonly diagnosed

genetic disorders to preterm SGA birth, morbidity, and mortality. The Pediatrix Clinical

Datawarehouse (CDW) contains detailed health records of these infants, including the presence

- of genetic disorders diagnosed during standard clinical care.
- 

## **Materials/Subjects and Methods:**

 This study was approved by the institutional review board of Columbia University with a waiver 85 for informed consent. This was a retrospective multicenter cohort study using the Pediatrix CDW. The CDW includes records from approximately 400 community and academic NICUs 87 (levels I–IV) in 35 US states and Puerto Rico, which provided care to approximately 20% of preterm infants born in the United States during the study period. Data was entered by clinicians using admission, progress, and discharge notes, as well as results from laboratory, imaging, and other diagnostic studies. These data were then extracted, consolidated, and processed to 91 populate the CDW.<sup>27</sup> Data included demographic and maternal characteristics, diagnoses made by clinicians (genetic disorders, morbidities), and hospital disposition (mortality, discharge home, or transfer). The results of negative test results, including for genetic disorders, were not available. Records of 409 399 infants born from 23 to 33 weeks' gestation, discharged from 2000 to 2020 were extracted. Data from NICU admission to discharge were collected. Birth weight was normalized within the cohort by gestational age and sex. Cases were excluded if these data were missing. Infants were classified as SGA for normalized birth weight below the  $10<sup>th</sup>$  percentile or as appropriate for gestational age (AGA) at the 10<sup>th</sup> percentile or above and 99 less than the 90<sup>th</sup> percentile. Infants with birth weight greater than the 90<sup>th</sup> percentile were excluded to prevent the confounding impact of poor outcomes in LGA infants. We determined the overlap of this definition with SGA defined by Fenton criteria and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) consensus FGR 103 definition. $10,28$ 

 *Association of Genetic Disorders with SGA versus AGA birth among preterm infants* We performed multiple variable logistic regression of the association of the following maternal and infant characteristics: ethnicity/race (maternal self-declared), maternal age, diagnosis of genetic disorders, the presence of congenital anomalies (defined as clinician diagnosed anomalies of the heart, gastrointestinal tract, brain, lungs, kidneys and urinary tract, or the presence of hydrops), and year of discharge. Congenital anomalies themselves are strongly associated with genetic disorders. Therefore, we tested for an interaction between congenital anomalies and genetic disorders with the outcome of SGA birth.

 This analysis was also repeated limiting the cohort to infants born following singleton gestation to test the effect of multiple gestation. Unadjusted odds of SGA versus AGA birth were determined for each genetic disorder in which SGA birth was observed. The prevalence rate of SGA birth across maternal age was also determined.

 *Association of genetic disorders with morbidity and mortality within preterm SGA infants* Next, we evaluated factors associated with severe morbidity or mortality within preterm SGA infants. To limit ascertainment bias, infants transferred after birth or prior to discharge were 122 excluded from the analysis of clinical outcomes.<sup>29</sup> Multivariable logistic regression was performed for severe morbidity or mortality as a combined clinical outcome. Severe morbidity was defined as any of the following: acute kidney injury (AKI) defined by the diagnosis of oliguria or anuria (ICD-9 788.5 or ICD-10: R34); severe intracranial hemorrhage (ICH) defined as grade III or IV intraventricular hemorrhage by Papile criteria or cystic periventricular 127 leukomalacia; medically or surgically treated necrotizing enterocolitis (NEC); severe bronchopulmonary dysplasia (BPD) defined as invasive mechanical ventilation at 36 weeks' postmenstrual age; severe retinopathy of prematurity (ROP) defined as need for any medical or surgical intervention; culture-positive sepsis defined by any positive blood or urine culture; or

 shock defined as administration of any vasopressor or inotrope. The following were covariates: exposure to antenatal betamethasone, mode of delivery (vaginal delivery was treated as reference), phenotypic sex (female was treated as reference given the associated risk of 134 morbidity in male infants),  $31,32$  race (White race was treated as reference given thee proportional size), gestational age, birth weight Z-score, discharge year epoch (2000-2004, 2005-2009, 2010-2014, 2015-2020), intubation in the first 72 hours of life, presence of a known genetic disorder, and the presence of congenital anomalies. This analysis was repeated limiting the cohort to infants born following singleton gestation to test the effect of multiple gestations. As before, we also tested for an interaction between genetic disorders and congenital anomalies and the outcome of morbidity or mortality. Finally, we sought to evaluate how SGA preterm infants with or without congenital anomalies compared to AGA preterm infants with respect to rates of morbidity and mortality. Using AGA preterm infants as reference for both analyses, we determined the crude odds ratios (OR) of individual comorbidities for preterm infants born SGA without congenital anomalies and for preterm infants born SGA with congenital anomalies. Analyses were made using RStudio 147 version 2022.07.0 (R Project for Statistical Computing) (eMethods in the **Supplement**).<sup>33</sup> **Results** 378 887 SGA and AGA infants were identified in this cohort (**Table 1**). Of these, 176 791 (46.7%) were female. The mean (SD) gestational age was 30.1 (2.86) weeks, and the mean (SD) birth weight was 1.44 (0.49) kg. Genetic disorders were diagnosed in 5 386 (1.4%) infants. Congenital anomalies were present in 24 463 (6.4%) of infants. 36 985 (9.8%) infants were 154 defined as SGA. 36 985 infants met this definition, all of whom were below the  $10<sup>th</sup>$  percentile for NICHD fetal growth (**Supplemental Figure 1**). 33 451 (92.1%) of these infants were also below

156 the Fenton  $10<sup>th</sup>$  percentile definition of SGA birth.



8810 preterm SGA infants that experienced severe morbidity or mortality as compared to 415

 (2.1%) of the 20 173 preterm AGA infants that did not experience these outcomes. Antenatal betamethasone, birth in later years, maternal identification as Asian or Black (versus White), increased gestational age, and increased birth weight all were associated with lower adjusted odds of morbidity or mortality. Male sex, maternal identification as Hispanic (versus White), intubation in the first 72 hours of life, the presence of known genetic disorders, or congenital anomalies were associated with greater adjusted odds of morbidity or mortality. Nearly identical results were found for all covariates when this regression was limited to infants born following singleton gestation pregnancy (**Supplemental Figure 3**). Compared to AGA preterm infants, SGA preterm infants with or without other congenital anomalies experienced higher rates of death and every comorbidity, with the exception of severe ICH, which was observed to occur less frequently in infants with isolated SGA status compared to all AGA infants. (**Table 2**). As a secondary analysis, we repeated this regression with a test for an interaction between the presence of genetic disorders and the presence of any congenital anomaly. We found that SGA preterm infants with genetic disorders and congenital anomalies had an adjusted odds ratio (95% confidence interval) of 1.52 (1.03, 2.27) for severe morbidity or mortality.

#### **Discussion**

 The primary finding of our study was that genetic disorders were strongly and nonspecifically associated with preterm SGA birth, morbidity, and mortality. There are important strengths, limitations, and clinical implications of this finding. Our analysis revealed several secondary findings as well: lower birth weight and higher risk of illness in preterm infants with cystic fibrosis and hypophosphatasia, a synergistic risk of illness in infants with congenital anomalies and genetic disorders, and a lower rate of severe ICH in preterm SGA infants without congenital anomalies. In the following we discuss the primary and secondary findings of our research.

 Using a highly generalizable cohort, we found that commonly diagnosed genetic disorders were twice as prevalent in SGA infants compared to AGA infants, and that genetic disorders were strongly associated with SGA birth weight after adjusting for known risk factors. Genetic disorders were also strongly associated with severe morbidity and mortality in this population. We confirmed previously described associations between common aneuploidies and SGA birth, morbidity, and mortality. Interestingly, we found a broad association between genetic disorders and preterm SGA birth. Of the 20 genetic disorders analyzed (including "unspecified" cases of aneuploidy or copy number variants), significant associations with SGA birth were found in 10, 216 and nonsignificant trends towards this association were found in 8. Cystic fibrosis has recently 217 been implicated as a cause of lower birth weight and earlier gestation of birth, which our data support. We also found evidence of a novel association between hypophosphatasia and preterm SGA birth, as well as significantly greater odds of morbidity or mortality. If confirmed, these findings might illuminate pathogenic mechanisms of growth restriction. Multiple gestations have typically been excluded in large cohort studies limiting the generalizability of findings. We found similar results with or without this exclusion. However, we

 did not evaluate pairwise outcomes within twin or greater multiple gestations. Clinicians and families, particularly in the setting of growth discordant twins, often must consider risks and benefits in timing of delivery. Targeted focus on SGA multiple gestations could help better 227 inform these decisions, as well as validate twin-specific growth charts.<sup>35</sup> Unique factors in twin pregnancies including unequal placentation, twin-twin transfusion, and birth weight discordance 229 all may influence clinical outcomes, and should be explored further.  $36,37$ 

 In addition to genetic disorders, we found that congenital anomalies were strongly associated with preterm SGA birth, morbidity, and mortality. Congenital anomalies of the kidney, heart,

brain, and other organ systems are themselves strongly linked to genetic disorders. It is unclear

 if anomalies themselves caused lower birth weight and illness, or if anomalies were the sentinel features of underlying genetic disorders. A parsimonious explanation is that underlying genetic disorders contribute to congenital anomalies, poor fetal growth, and severe morbidity. This is further supported by the finding that genetic disorders and congenital anomalies interacted to confer synergistically greater risk of morbidity and mortality in SGA preterm infants.

 Intriguingly, preterm SGA infants without congenital anomalies were found to have lower odds of severe ICH compared to AGA infants. Fetal growth restriction and SGA birth have been described as protective against severe intraventricular hemorrhage in extremely preterm (born < 243 28 weeks' gestation) infants.  $6,8,38-40$  The implication of a lower risk of severe ICH in SGA birth without other anomalies warrants attention given reports of higher risk of neurodevelopmental 245 impairment including poorer cognitive outcomes in this population.<sup>41</sup> Administration of antenatal corticosteroids reduces the risk of severe IVH and mortality, but studies have suggested that 247 steroids in SGA preterm infants may not reduce serious morbidities.<sup>42,43</sup> Although a previous landmark trial reported a potential reduction in severe IVH but no effect on neurosensory impairment with the use of prophylactic indomethacin in extremely low birth weight infants, 250 multiple studies have refuted this finding.<sup>44-46</sup> Replication, functional validation, and basic investigation into protection of IVH in growth restricted extremely preterm infants may inform novel therapies.

 Our study had several compelling strengths. This represents the largest and most comprehensive examination of factors associated with preterm SGA status and comorbidities to our knowledge. This was a multicenter investigation of infants from diverse backgrounds, with generalizable results. There are important limitations to this study. Infants born SGA may be more likely to undergo pre- or postnatal genetic testing, especially in the presence of other congenital anomalies or comorbidities. Details regarding testing, including time (pre- or

 postnatal) and indication are unknown in this cohort. Genetic testing has also undergone dramatic changes from 2000 to 2020. There is likely substantial heterogeneity in the genetic workups performed across this period. Unfortunately, data are not available regarding the spectrum of testing performed in the cohort, including negative results. There may also be heterogeneity in the assignment of gestational age. The method used to determine this for each individual in the cohort is unknown. Additionally, SGA and FGR are defined differently in the literature of this field. We defined SGA birth here using the distribution of birth weight found within this cohort. This definition increases the internal validity or our analysis but may limit generalization. Given that our definition of SGA shared 92.1% with Fenton-defined SGA infants, this is unlikely. The optimal criteria for defining a newborn as SGA or growth restricted likely include individual environmental, genetic, and biological factors, many of which are yet unknown. These analyses also did not consider when growth restriction occurred during pregnancy, patterns of growth restriction (such as head-sparing or symmetric), fetal exposures, postnatal growth patterns, or social determinants of health. Our dataset lacks maternal records, including the presence of comorbidities that may contribute to placental insufficiency. Our finding that extremes of maternal age, as well as increasing maternal age from 18 to 34 years, were associated with SGA status likely reflects the contribution of these maternal factors.

 Genetic counseling and consideration of testing for FGR is recommended by the American College of Obstetricians and Gynecologists as well as by the Society for Maternal and Fetal 280 Medicine.<sup>47,48</sup> There is not yet consensus regarding the postnatal evaluation of SGA infants.<sup>49,50</sup> Scarce data exist regarding how often genetic workups or testing are actually performed pre- or postnatally for these indications. Furthermore, perinatal genetic disorders often present 283 nonspecifically and are often diagnosed belatedly.<sup>51,52</sup> The indications and potential benefit for genetic testing in this population is unknown without prospective, genome-wide testing.

 Our findings have implications for clinical practice and further research. Clinicians should strongly consider genetic testing of preterm SGA infants, particularly in the setting of other comorbidities or anomalies. Genetic disorders were found in 3.0% of preterm SGA infants overall and 4.3% of preterm SGA infants with severe morbidity and mortality. These represent underestimates as prospective testing was not preformed. Without prospective genetic testing the baseline rate genetic disorders in this population is unknown. Preterm SGA infants with genetic disorders or congenital anomalies may be at higher risk for morbidity and mortality. Clinicians should consider this risk when counseling families, evaluating the risks and benefits of management decisions, or estimating the pre-test probability of diagnostic tests. Prospective genomic research is urgently needed to clarify the contribution of genetic disorders to disease in this population. 

# **Acknowledgements**

- The authors wish to gratefully acknowledge Dr. Ali G. Gharavi (Columbia University Irving
- Medical Center) and his research team, as well as Dr. Joseph M. Feinglass (Feinberg School of
- Medicine, Northwestern University) for their mentorship and thoughtful review of this project.

- Authors TH and JEM are supported by *Thrasher Research Fund Early Career Awards.* TH is
- also supported by the *NIH National Center for Advancing Translational Sciences*
- (KL2TR001874).

# **Supplemental Materials**

- **Supplemental Table 1.** Unadjusted odds of SGA birth within diagnosed genetic disorders.
- **Supplemental Figure 1.** Classification of SGA or FGR birth in this cohort by related criteria.
- **Supplemental Figure 2.** Multivariable logistic regression for SGA versus AGA status in preterm
- infants with singleton gestation.
- **Supplemental Figure 3.** Multivariable logistic regression for severe morbidity or mortality in
- SGA preterm infants following singleton gestation.
- **eMethods.** R studio script used for this project.





319 Abbreviations: AGA (appropriate for gestational age), SGA (small for gestational age)

**OR (99.44% CI)**

# **Outcome Preterm SGA Infants without Congenital Anomalies (versus AGA Preterm Infants) Preterm SGA Infants with Additional Congenital Anomalies (versus AGA Preterm Infants)** Mortality or any morbidity 1.45 (1.39, 1.50) 4.86 (4.33, 5.46) Mortality 1.99 (1.87, 2.12) 5.96 (5.20, 6.83) Acute kidney injury 1.60 (1.46, 1.75) 5.03 (4.22, 6.00) Severe intracranial hemorrhage  $0.82 (0.75, 0.91)$  1.89 (1.52, 2.36) Severe necrotizing enterocolitis 1.28 (1.18, 1.40) 3.50 (2.91, 4.21) Severe bronchopulmonary dysplasia 2.40 (2.13, 2.70) 9.50 (7.78, 11.59) Severe retinopathy of prematurity 1.52 (1.33, 1.74) 3.14 (2.31, 4.27) Sepsis 3.22 (2.81, 3.68) 3.22 (2.81, 3.68) Shock 1.35 (1.28, 1.43) 3.18 (2.78, 3.64) 321 Abbreviations: CI (confidence interval), OR (odds ratio), SGA (small for gestational age)

# 320 **Table 2.** Unadjusted odds of mortality or severe morbidities in preterm SGA infants.

322

323



 **Figure 1:** Multivariable regression of clinical characteristics of preterm infants born SGA versus AGA. Regression was performed for the outcome of SGA birth within infants born before 34 weeks' gestation. Maternal identification as Hispanic was associated with lower adjusted odds of SGA status. Maternal identification as Asian or Black, advancing maternal age, the presence of a known genetic disorder, and the presence of congenital anomalies (excluding hydrops and pulmonary anomalies) were associated with greater adjusted odds of SGA status.



334<br>335

**Figure 2.** Multivariable logistic regression of clinical characteristics of preterm SGA infants with severe morbidity or mortality (versus preterm SGA infants without severe morbidity or mortality). Within the subset of preterm infants born SGA, regression was performed against the combined outcome of mortality or severe morbidity. Antenatal betamethasone, maternal identification as Asian or Black, increasing gestational age, increasing birth weight, cesarean delivery, and later epochs were found to be associated with lower adjusted odds of the composite outcome. Male sex, maternal identification as Hispanic, intubation after birth, and the presence of known genetic disorders or congenital anomalies were associated with greater adjusted odds of the composite outcome.



 **Figure 3.** Prevalence of SGA birth by maternal age. The prevalence of SGA birth was determined (within preterm births) for each year of maternal age from 15 to 50. Error bars depict the 95% CI. Extreme maternal ages, less than 15 and greater than 50, were excluded from the analysis due to their small sample size. For each one year increase in maternal age, on 351 average, there was a 0.107 increase in SGA prevalence per 100 preterm births (adjusted  $r^2$  = 352  $0.46$ ,  $p = 0.001$ ). 

- 
- 
- 
- 

 1. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford

# **References**

 Network. *Am J Obstet Gynecol*. Jan 2000;182(1 Pt 1):198-206. doi:10.1016/s0002- 9378(00)70513-8 2. Zeitlin J, El Ayoubi M, Jarreau PH, et al. Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort. *J Pediatr*. Nov 2010;157(5):733-9.e1. doi:10.1016/j.jpeds.2010.05.002 3. Peacock JL, Lo JW, D'Costa W, Calvert S, Marlow N, Greenough A. Respiratory morbidity at follow-up of small-for-gestational-age infants born very prematurely. *Pediatr Res*. Apr 2013;73(4 Pt 1):457-63. doi:10.1038/pr.2012.201 4. De Jesus LC, Pappas A, Shankaran S, et al. Outcomes of small for gestational age infants born at <27 weeks' gestation. *J Pediatr*. Jul 2013;163(1):55-60.e1-3. doi:10.1016/j.jpeds.2012.12.097 5. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and mortality among premature neonates. *Am J Obstet Gynecol*. Aug 2004;191(2):481-7. doi:10.1016/j.ajog.2004.01.036 6. Mendez-Figueroa H, Truong VT, Pedroza C, Chauhan SP. Morbidity and Mortality in Small-for-Gestational-Age Infants: A Secondary Analysis of Nine MFMU Network Studies. *Am J Perinatol*. Mar 2017;34(4):323-332. doi:10.1055/s-0036-1586502 7. Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. *Pediatrics*. Jun 2012;129(6):1019-26. doi:10.1542/peds.2011-3028 8. Baer RJ, Rogers EE, Partridge JC, et al. Population-based risks of mortality and preterm morbidity by gestational age and birth weight. *J Perinatol*. Nov 2016;36(11):1008-1013. doi:10.1038/jp.2016.118 9. Minor KC, Bianco K, Sie L, Druzin ML, Lee HC, Leonard SA. Severity of small-for- gestational-age and morbidity and mortality among very preterm neonates. *J Perinatol*. Apr 2023;43(4):437-444. doi:10.1038/s41372-022-01544-w 10. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatr*. Apr 20 2013;13:59. doi:10.1186/1471-2431-13-59 11. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. *J Clin Endocrinol Metab*. Mar 2007;92(3):804-10. doi:10.1210/jc.2006-2017 12. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. *Pediatrics*. Jun 2003;111(6 Pt 1):1253-61. doi:10.1542/peds.111.6.1253 13. Katz J, Lee AC, Kozuki N, et al. Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis. *Lancet*. Aug 3 2013;382(9890):417-425. doi:10.1016/s0140-6736(13)60993-9 14. Finken MJJ, van der Steen M, Smeets CCJ, et al. Children Born Small for Gestational Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications. *Endocr Rev*. Dec 1 2018;39(6):851-894. doi:10.1210/er.2018-00083 15. McCowan L, Horgan RP. Risk factors for small for gestational age infants. *Best Pract Res Clin Obstet Gynaecol*. Dec 2009;23(6):779-93. doi:10.1016/j.bpobgyn.2009.06.003 16. Wollmann HA. Intrauterine growth restriction: definition and etiology. *Horm Res*. 1998;49 Suppl 2:1-6. doi:10.1159/000053079

 17. Mone F, Mellis R, Gabriel H, et al. Should we offer prenatal exome sequencing for intrauterine growth restriction or short long bones? A systematic review and meta-analysis. *Am J Obstet Gynecol*. Oct 7 2022;doi:10.1016/j.ajog.2022.09.045 18. Meler E, Sisterna S, Borrell A. Genetic syndromes associated with isolated fetal growth restriction. *Prenat Diagn*. Mar 2020;40(4):432-446. doi:10.1002/pd.5635 19. Peng R, Yang J, Xie HN, Lin MF, Zheng J. Chromosomal and subchromosomal anomalies associated to small for gestational age fetuses with no additional structural anomalies. *Prenat Diagn*. Dec 2017;37(12):1219-1224. doi:10.1002/pd.5169 20. Borrell A, Grande M, Meler E, et al. Genomic Microarray in Fetuses with Early Growth Restriction: A Multicenter Study. *Fetal Diagn Ther*. 2017;42(3):174-180. doi:10.1159/000452217 21. Motelow JE, Lippa NC, Hostyk J, et al. Risk Variants in the Exomes of Children With Critical Illness. *JAMA Netw Open*. Oct 3 2022;5(10):e2239122. doi:10.1001/jamanetworkopen.2022.39122 22. Stanley KE, Giordano J, Thorsten V, et al. Causal Genetic Variants in Stillbirth. *N Engl J Med*. Sep 17 2020;383(12):1107-1116. doi:10.1056/NEJMoa1908753 23. Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. *Lancet*. Feb 23 2019;393(10173):758- 767. doi:10.1016/S0140-6736(18)32042-7 24. Lord J, McMullan DJ, Eberhardt RY, et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study. *Lancet*. Feb 23 2019;393(10173):747-757. doi:10.1016/S0140-6736(18)31940-8 25. Bertoli-Avella AM, Beetz C, Ameziane N, et al. Successful application of genome sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort. *Eur J Hum Genet*. Jan 2021;29(1):141-153. doi:10.1038/s41431-020-00713-9 26. Hays T, Wapner RJ. Genetic testing for unexplained perinatal disorders. *Curr Opin Pediatr*. Apr 1 2021;33(2):195-202. doi:10.1097/MOP.0000000000000999 27. Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system--tools for "meaningful use" in continuous quality improvement. *Clin Perinatol*. Mar 2010;37(1):49-70. doi:10.1016/j.clp.2010.01.016 28. Grantz KL, Grewal J, Kim S, et al. Unified standard for fetal growth: the Eunice Kennedy Shriver National Institute of Child Health and Human Development Fetal Growth Studies. *Am J Obstet Gynecol*. Apr 2022;226(4):576-587.e2. doi:10.1016/j.ajog.2021.12.006 29. Tolia VN, Clark RH. The Denominator Matters! Lessons from Large Database Research in Neonatology. *Children (Basel)*. Nov 7 2020;7(11):216-216. doi:10.3390/children7110216 30. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. *J Pediatr*. Apr 1978;92(4):529-34. doi:10.1016/s0022-3476(78)80282-0 31. Stevenson DK, Verter J, Fanaroff AA, et al. Sex differences in outcomes of very low birthweight infants: the newborn male disadvantage. *Arch Dis Child Fetal Neonatal Ed*. Nov 2000;83(3):F182-5. doi:10.1136/fn.83.3.f182 32. Peacock JL, Marston L, Marlow N, Calvert SA, Greenough A. Neonatal and infant outcome in boys and girls born very prematurely. *Pediatr Res*. Mar 2012;71(3):305-10. doi:10.1038/pr.2011.50 33. *R: A language and environment for statistical computing.* R Foundation for Statistical Computing; 2022. https://www.R-project.org/ 34. Schlüter DK, Griffiths R, Adam A, et al. Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales. *Thorax*. 2019;74(5):447-454.

doi:10.1136/thoraxjnl-2018-211706

 35. Giorgione V, Briffa C, Di Fabrizio C, Bhate R, Khalil A. Perinatal Outcomes of Small for Gestational Age in Twin Pregnancies: Twin vs. Singleton Charts. *J Clin Med*. Feb 8 2021;10(4)doi:10.3390/jcm10040643 36. D'Antonio F, Khalil A, Dias T, Thilaganathan B. Weight discordance and perinatal mortality in twins: analysis of the Southwest Thames Obstetric Research Collaborative (STORK) multiple pregnancy cohort. *Ultrasound Obstet Gynecol*. Jun 2013;41(6):643-8. doi:10.1002/uog.12412 37. Townsend R, Khalil A. Fetal growth restriction in twins. *Best Pract Res Clin Obstet Gynaecol*. May 2018;49:79-88. doi:10.1016/j.bpobgyn.2018.02.004 38. Kim F, Bateman DA, Goldshtrom N, Sheen J-J, Garey D. Intracranial ultrasound abnormalities and mortality in preterm infants with and without fetal growth restriction stratified by fetal Doppler study results. *Journal of Perinatology*. 2023/01/30 2023;doi:10.1038/s41372- 023-01621-8 39. Procianoy RS, Garcia-Prats JA, Adams JM, Silvers A, Rudolph AJ. Hyaline membrane disease and intraventricular haemorrhage in small for gestational age infants. *Arch Dis Child*. Jul 1980;55(7):502-5. doi:10.1136/adc.55.7.502 40. Gilbert WM, Danielsen B. Pregnancy outcomes associated with intrauterine growth restriction. *American Journal of Obstetrics and Gynecology*. 2003/06/01/ 2003;188(6):1596- 1601. doi:https://doi.org/10.1067/mob.2003.384 41. Sacchi C, Marino C, Nosarti C, Vieno A, Visentin S, Simonelli A. Association of Intrauterine Growth Restriction and Small for Gestational Age Status With Childhood Cognitive Outcomes: A Systematic Review and Meta-analysis. *JAMA Pediatr*. Aug 1 2020;174(8):772- 781. doi:10.1001/jamapediatrics.2020.1097 42. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*. Mar 21 2017;3(3):Cd004454. doi:10.1002/14651858.CD004454.pub3 43. Blankenship SA, Brown KE, Simon LE, Stout MJ, Tuuli MG. Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM*. Nov 2020;2(4):100215. doi:10.1016/j.ajogmf.2020.100215 44. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. *N Engl J Med*. Jun 28 2001;344(26):1966-72. doi:10.1056/nejm200106283442602 45. Mirza H, Laptook AR, Oh W, et al. Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants. *Arch Dis Child Fetal Neonatal Ed*. Sep 2016;101(5):F418-22. doi:10.1136/archdischild-2015- 309112 46. Foglia EE, Roberts RS, Stoller JZ, Davis PG, Haslam R, Schmidt B. Effect of Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk of Severe Intraventricular Hemorrhage. *Neonatology*. 2018;113(2):183-186. doi:10.1159/000485172 47. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. *Obstet Gynecol*. Feb 1 2021;137(2):e16-e28. doi:10.1097/aog.0000000000004251 48. Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). *Am J Obstet Gynecol*. Oct 2020;223(4):B2-b17. doi:10.1016/j.ajog.2020.05.010 49. Dauber A. Genetic Testing for the Child With Short Stature-Has the Time Come To Change Our Diagnostic Paradigm? *J Clin Endocrinol Metab*. Jul 1 2019;104(7):2766-2769. doi:10.1210/jc.2019-00019 50. Rapaport R, Wit JM, Savage MO. Growth failure: 'idiopathic' only after a detailed diagnostic evaluation. *Endocr Connect*. Mar 2021;10(3):R125-r138. doi:10.1530/ec-20-0585

- 51. Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected
- genetic diseases. *NPJ Genom Med*. 2018;3(1):16. doi:10.1038/s41525-018-0053-8
- 52. Wojcik MH, Schwartz TS, Yamin I, et al. Genetic disorders and mortality in infancy and
- early childhood: delayed diagnoses and missed opportunities. *Genet Med*. Nov
- 2018;20(11):1396-1404. doi:10.1038/gim.2018.17





516<br>517 517 Abbreviations: AGA (appropriate for gestational age), CI (confidence interval), OR (odds ratio), 518 SGA (small for gestational age)

SGA (small for gestational age)



 **Supplemental Figure 1.** Classification of SGA or FGR birth in this cohort by related criteria. This cohort included 409,399 preterm infants from the Pediatrix CDW. SGA was defined for this 537 study as below the  $10<sup>th</sup>$  percentile for gestational age and sex within the CDW cohort. 36,985 538 infants met this definition, all of whom were below the  $10<sup>th</sup>$  percentile for NICHD fetal growth. 539 33,451 (92.1%) of these infants also fell below the Fenton 10<sup>th</sup> percentile definition of SGA birth. The numbers of infants meeting these criteria are depicted in the Euler diagram above.



**Supplemental Figure 2.** Multivariable logistic regression for SGA versus AGA status in preterm

infants with singleton gestation. The outcome of preterm SGA status was modeled as before

(**Figure 1**) in only infants born following singleton gestation. Nearly identical adjusted odds were

found for all covariates.



5 1020 50 U.51 Z

**Supplemental Figure 3.** Multivariable logistic regression for severe morbidity or mortality in

SGA preterm infants following singleton gestation. The combined outcome of mortality or severe

morbidity status for preterm SGA infants was modeled as before (**Figure 2**) in only infants born

following singleton gestation. Nearly identical adjusted odds were found for all covariates.

```
557 eMethods
558
559 The following script was used to generate tables and figures. The script was created using RStudio 
          (version 2022.07.0).
561<br>562
          562 #### Table 1
563<br>564
          ## Import Data
565
566 setwd("/Users/Miles/Desktop")<br>567 Prevalence <- read.csv("Prev
567 Prevalence <- read.csv("Prev_Update_GxDx.csv")<br>568 Prevalence1 <- Prevalence
           Prevalence1 <- Prevalence
569 library(dplyr)<br>570 library(table1
           library(table1)
571<br>572
          ## Data cleaning
573<br>574
          574 Prevalence2 <- Prevalence1 %>% filter(BW_Z_Score <= 1.282)
575<br>576
576 Prevalence3 <- Prevalence2 %>% mutate(SGA = case_when (BW_Z_S) Score < -1.282 ~ 'SGA', 577 BW Z Score >= -1.282 ~ 'AGA'))
          BW Z Score >= -1.282 ~ 'AGA'))
578<br>579
          Prevalence4 <- Prevalence3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present"))
580
581 Prevalence4$DY <- as.factor(ifelse(Prevalence4$DischargeYear < 2005, "2000 to 2004", 582 ifelse(Prevalence4$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4$Discharge
          582 ifelse(Prevalence4$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4$DischargeYear < 2015, 
583 "2010 to 2014", "2015 to 2020"))))
584<br>585
          ## Label Data
586<br>587
587 label(Prevalence4$BW) <- "Birthweight (kg)"
588 label(Prevalence4$GA) <- "Gestational Age (weeks)"<br>589 label(Prevalence4$GxDx) <- "Known Genetic Disorde
589 label(Prevalence4$GxDx) <- "Known Genetic Disorder"<br>590 label(Prevalence4$Any Anom) <- "Congenital Anomaly
590 label(Prevalence4$Any_Anom) <- "Congenital Anomaly"<br>591 label(Prevalence4$SGA) <- "SGA Birth"
591 label(Prevalence4$SGA) <- "SGA Birth"<br>592 label(Prevalence4$Genetic) <- "Genetic
          label(Prevalence4$Genetic) <- "Genetic Disorder"
593<br>594
          ## Calculate p-values for Table1
595<br>596
596 pvalue <- function(x, ...) {<br>597 # Construct vectors of da
597 # Construct vectors of data y, and groups (strata) g<br>598 v \le v unlist(x)
            y <- unlist(x)
599 g \leq 5 factor(rep(1:length(x), times=sapply(x, length)))
600 if (is.numeric(y)) {<br>601 # For numeric va
             # For numeric variables, perform a standard 2-sample t-test
602 p \leq t.test(y \sim g)$p.value
603 } else {<br>604 # For
              # For categorical variables, perform a chi-squared test of independence
605 p \leq - chisq.test(table(y, g))$p.value
606 }
607 # Format the p-value, using an HTML entity for the less-than sign.<br>608 # The initial empty string places the output on the line below the va
608 \# The initial empty string places the output on the line below the variable label.<br>609 \frac{1}{100} c("", sub("<", "&lt;", format.pval(p. digits=3, eps = 1e-200)))
            c("", sub("<", "<", "format.pval(p, digits=3,eps = 1e-200)))610 }
611<br>612
          ## Table 1
```

```
613<br>614
        table1(\sim Sex + GA + Race + MaternalAge + DY + Genetic + Any Anom |SGA, data=Prevalence4,
615 overall=F, extra.col=list(`P-value`=pvalue))
616
617 ####Table 2:
618<br>619
        ##Inport Data
620
621 setwd("/Users/Miles/Desktop")
622 Outcome <- read.csv("Outcome_Update_GxDx.csv")
        Outcome1 <- Outcome
624 library(dplyr)
625
626 ## Clean the data and make new varriables
627<br>628
628 Outcome2 <- Outcome1 %>% mutate(SGA = case_when (BW_Z_S) = -1.282 \sim 11, BW_Z_S = -1.282 \sim 0)
        (1.282 - '0')630<br>631
        631 Outcome3 <- Outcome2 %>% filter(BW_Z_Score <= 1.282)
632
633 Outcome4 <- Outcome3 %>% mutate(Additional_Anom = ifelse(Any_Anom == "Absent", "0", "1"))
634<br>635
        ##Perfom sum calculations
636 sum(Outcome4$SGA == "1" & Outcome4$Additional_Anom == "1" & Outcome4$CritIllorDeath == "Y") 
637 ##Used this model for all the possible scenarios and then put them into an excel sheet 
638 ##Excel Table 2 and Figure_2 were created for export 
639<br>640
        ## Load packages
641<br>642
642 library(tidyverse)<br>643 library(pixiedust)
        library(pixiedust)
644 library(kableExtra)
645 library(webshot)
646<br>647
        ##Load data
648<br>649
        Pos <-read.csv("Figure_2_Bonferroni_Corrected.csv")
650<br>651
        tbl1 <- dust(Pos)
652<br>653
        ##Plot
654
655 tbl1 %>%
656 sprinkle_colnames(Outcome = "Outcome*", Isolated = "Isolated SGA", Syndromic= "SGA with Additional 657 Congenital Anomaly") %>%
        657 Congenital Anomaly") %>%
658 kable() %>% kable_styling() %>%<br>659 add header above(c(" " = 1, "OR
         add header above(c(" " = 1, "OR (95% CI)" = 2))%>%
660 kable classic(full width = F, html font = "Arial") %>%
661 footnote("AKI: acute kidney injury, ICH: intracranial hemorrhage, NEC: necrotizing enterocolitis, BPD: 
662 bronchopulmonary dysplasia, ROP: retinopathy of prematurity", general_title = "*Abbreviations")
663
664 ####Figure 1
```
665<br>666 ##import data

667<br>668 setwd("/Users/Miles/Desktop") 669 Prevalence <- read.csv("Prev\_Update\_GxDx.csv")<br>670 Prevalence1 <- Prevalence Prevalence1 <- Prevalence 671 library(dplyr) 672 673 ##clean data and make new variables 674<br>675 675 Prevalence2 <- Prevalence1 %>% filter(BW\_Z\_Score <= 1.282) 676 Prevalence3 <- Prevalence2 %>% mutate(SGA = case\_when  $(BW_Z_Score < -1.282 \sim '1', BW_Z_Score$  677 >= -1.282 ~ '0')) 677  $>= -1.282 \sim 0')$ <br>678 Prevalence4 <-1 678 Prevalence4 <- Prevalence3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present")) 679 Prevalence4\$MA <- as.factor(ifelse(Prevalence4\$MaternalAge < 20, "10-19", 680 ifelse(Prevalence4\$MaternalAge < 30, "20-29", ifelse(Prevalence4\$MaternalAge < 40, "30-39", 681 ifelse(Prevalence4\$MaternalAge < 50, "40-49", "50-60"))))) 682 Prevalence4\$Any\_Anom <- as.factor(ifelse(Prevalence4\$Any\_Anom == "AG", "Genital", 683 ifelse(Prevalence4\$Any\_Anom == "CAKUT", "Renal", ifelse(Prevalence4\$Any\_Anom == "CHD", "Cardiac", ifelse(Prevalence4\$Any\_Anom == "CNS", "Neurological", ifelse(Prevalence4\$Any\_Anom == 685 "GI", "Gastrointestinal", ifelse(Prevalence4\$Any\_Anom == "Pulm", "Pulmonary", 686 ifelse(Prevalence4\$Any\_Anom == "Hydrops", "Hydrops", ifelse(Prevalence4\$Any\_Anom == "Multiple", "Multiple", "Absent"))))))))))) 688 Prevalence4\$DY <- as.factor(ifelse(Prevalence4\$DischargeYear < 2005, "2000 to 2004", 689 ifelse(Prevalence4\$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4\$DischargeYear < 2015, "2010 to 2014", "2015 to 2020")))) 691<br>692 ##load packages 693<br>694 694 library(Hmisc)<br>695 library(expss) 695 library(expss)<br>696 library(gtsumr 696 library(gtsummary)<br>697 library(forestmodel) 697 library(forestmodel)<br>698 library(lme4) library(lme4) 699 700 ##label data 701 702 Prevalence4\$DischargeYear <- factor(Prevalence4\$DischargeYear) 703 Prevalence4\$Race <- factor(Prevalence4\$Race) 704 705 Prevalence4\$Race <- relevel(Prevalence4\$Race, ref = "White")<br>706 Prevalence4\$SGA <-factor(Prevalence4\$SGA) 706 Prevalence4\$SGA <-factor(Prevalence4\$SGA) 707 Prevalence4\$Race <- factor(Prevalence4\$Race)<br>708 Prevalence4\$Sex <- factor(Prevalence4\$Sex) 708 Prevalence4\$Sex <- factor(Prevalence4\$Sex)<br>709 Prevalence4\$Any Anom <- factor(Prevalence4 709 Prevalence4\$Any\_Anom <- factor(Prevalence4\$Any\_Anom)<br>710 Prevalence4\$MA <- factor(Prevalence4\$MA) 710 Prevalence4\$MA <- factor(Prevalence4\$MA)<br>711 Prevalence4\$DY <- factor(Prevalence4\$DY) Prevalence4\$DY <- factor(Prevalence4\$DY) 712 713 label(Prevalence4\$MA) <- "Maternal Age (years)"<br>714 label(Prevalence4\$Race) <- "Race and Ethnicity" label(Prevalence4\$Race) <- "Race and Ethnicity" 715 label(Prevalence4\$Genetic) <- "Genetic Disorder" 716 label(Prevalence4\$Any\_Anom) <- "Congenital Anomaly" 717 label(Prevalence4\$DY) <- "Discharge Year" 718 719 ##multiple variable logistic regression model<br>720 LogReg3 <- glm(SGA~ Race + MA + DY + G LogReg3 <- glm(SGA~ Race + MA + DY + Genetic + Any Anom, data = Prevalence4, family = 721 "binomial")<br>722 ##table dep

##table depiction of model

723 forest model(LogReg3, factor separate line = FALSE) 724 725 **####Figure 2:** 726  $##$ l oad data 728 729 setwd("/Users/Miles/Desktop")<br>730 Outcome <- read.csv("Outcom Outcome <- read.csv("Outcome\_Update\_GxDx.csv") 731 Outcome1 <- Outcome<br>732 library(dplyr) library(dplyr) 733 734 ##data preparation 735 736 Outcome2 <- Outcome1 %>% filter(BW\_Z\_Score <= 1.282) 737 Outcome3 <- Outcome2 %>% mutate(SGA = case\_when (BW\_Z\_Score < -1.282 ~ '1', BW\_Z\_Score >= -<br>738 1.282 ~ '0')) 738 1.282 ~ '0'))<br>739 Outcome4 < 739 Outcome4 <- Outcome3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present")) 740 Outcome5 <- Outcome4 %>% filter(SGA == "1")<br>741 Outcome5\$DY <- as.factor(ifelse(Outcome5\$Dis 741 Outcome5\$DY <- as.factor(ifelse(Outcome5\$DischargeYear < 2005, "2000 to 2004", 742 ifelse(Outcome5\$DischargeYear < 2010, "2005 to 2009", ifelse(Outcome5\$DischargeYear < 2015, "2010 743 to 2014", "2015 to 2020"))))<br>744 Cutcome6 <- Outcome5 %> 744 Outcome6 <- Outcome5 %>% mutate(AntSter = ifelse(Antenatal.Steroids == "0", "No", "Yes"))<br>745 Outcome7 <- Outcome6 %>% mutate(MV72 = ifelse(MVD0.2 == "N", "No", "Yes")) Outcome7 <- Outcome6 %>% mutate(MV72 = ifelse(MVD0.2 == "N", "No", "Yes")) 746 Outcome8 <- Outcome7 %>% filter(Deliv\_Mode == "Cesarean Section" | Deliv\_Mode == "Vaginal<br>747 Delivery") Delivery") 748<br>749 ##load required packages 750 751 library(expss)<br>752 library(gtsumr 752 library(gtsummary)<br>753 library(forestmodel) 753 library(forestmodel)<br>754 library(lme4) library(lme4) 755 library(Hmisc) 756 ##Label data 758 759 Outcome8\$Sex <- factor(Outcome8\$Sex) 760 Outcome8\$Race <- factor(Outcome8\$Race)<br>761 Outcome8\$AntSter <- factor(Outcome8\$AntS 761 Outcome8\$AntSter <- factor(Outcome8\$AntSter) 762 Outcome8\$CritIllorDeath <- factor(Outcome8\$CritIllorDeath)<br>763 Outcome8\$MV72 <- factor(Outcome8\$MV72) 763 Outcome8\$MV72 <- factor(Outcome8\$MV72)<br>764 Outcome8\$DY <- factor(Outcome8\$DY) Outcome8\$DY <- factor(Outcome8\$DY) 765<br>766 Outcome8\$Sex <- relevel(Outcome8\$Sex, ref = "Female") 767 Outcome8\$Race <- relevel(Outcome8\$Race, ref = "White") 768 label(Outcome8\$AntSter) <- "Antenatal Steroids" 770 label(Outcome8\$Race) <- "Race and Ethnicity" 771 label(Outcome8\$Genetic) <- "Genetic Disorder" 772 label(Outcome8\$Any\_Anom) <- "Congenital Anomaly"<br>773 label(Outcome8\$DY) <- "Discharge Year" 773 label(Outcome8\$DY) <- "Discharge Year" 774 label(Outcome8\$MV72) <- "MV within 72 Hours"<br>775 label(Outcome8\$GA) <- "Gestational Age (weeks label(Outcome8\$GA) <- "Gestational Age (weeks)" 776 label(Outcome8\$BW\_Z\_Score) <- "Birth Weight (Z-score)" 777

778 ## multiple variable logistic regression model 779 780 LogReg <- glm(CritlllorDeath ~ AntSter + Sex + Race + GA + BW\_Z\_Score + Deliv\_Mode + DY + MV72<br>781 + Genetic + Any Anom, data = Outcome8, family = "binomial") + Genetic + Any Anom, data = Outcome8, family = "binomial") 782 ##table depiction of model 784<br>785 forest\_model(LogReg, factor\_separate\_line = FALSE) 786 787 **####Figure 3:** 788 789 ##load data 790 791 setwd("/Users/Miles/Desktop") 792 Prevalence <- read.csv("MA\_V\_Prev\_per\_100\_Garphing.csv")<br>793 Prevalence1 <- Prevalence Prevalence1 <- Prevalence 794<br>795 ##uplaod required packages 796 library(dplyr) 798 library("ggplot2") 799 800 801 ##define and make plot 802 803 df <- ggplot(Prevalence1, aes(MA, Prev\_Per\_100)) + geom\_point() + geom\_errorbar(aes(ymin = 804 Low per 100, ymax = Upp per 100)) Low per 100, ymax = Upp per  $100$ )) 805 806 df + geom\_point() + scale\_x\_continuous(breaks=seq(0, 60, 5)) + labs (x = 'Maternal Age (Years)', y = 807 'SGA Prevalence per 100 Preterm Births') + theme bw() + theme(panel.border = element blank(), 807 'SGA Prevalence per 100 Preterm Births') + theme\_bw() + theme(panel.border = element\_blank(), 808 panel.grid.major = element blank(), 808 panel.grid.major = element\_blank(),<br>809 809 panel.grid.minor = element line(colour = "black")) panel.grid.minor = element blank(), axis.line = element line(colour = "black") element blank(), axis.line = element line(colour = "black")) 811 812 **####Running a linear regression** 813 Reg <- lm(Prev\_per\_100 ~ MA, data = MA\_V\_Prev\_per\_100\_Graphing.csv) 814 ##Review the results 815 Summary(Reg) 816 817 818 **####Supplemental table 1** 819 ##Inport Data 820 821 setwd("/Users/Miles/Desktop")<br>822 GxDx <- read.csv("Updated G GxDx <- read.csv("Updated\_GxDx\_SGA.csv") 823<br>824 ##Upload Packages

```
825<br>826
         library(dplyr)
827 library(tidyverse)<br>828 library(pixiedust)
828 library(pixiedust)<br>829 library(kableExtra
829 library(kableExtra)<br>830 library(webshot)
         library(webshot)
831<br>832
         ##Make Table Backend
833
834 GxDx2 <- replace(GxDx, is.na(GxDx), "")
835<br>836
         tbI3 \leq dust(GxDx2)837
838
839 ##Make the Table
840<br>841
841 tbl3 %>%<br>842 sprinkl
            sprinkle_colnames(Genetic.Diagnosis = "Genetic Diagnosis", SGA = "SGA", AGA= "AGA", Crude.OR
843 = "Crude OR", X95_low = "Low 95 CI", X95_high = "High 95 CI") %>% kable() %>% kable_styling()<br>844 %>%
844 %>%
            kable_classic(full_width = F, html_font = "Arial") %>%
846 row_spec(1,bold=T,hline_after = T) %>%<br>847 row spec(9,bold=T,hline_after = T) %>%
847 row_spec(9,bold=T,hline_after = T) %>%<br>848 row_spec(14,bold=T,hline_after = T) %>%
            row_spec(14,bold=T,hline_after = T) %>%
849 row_spec(21,bold=T,hline_after = T) %>%<br>850 add indent(c(2,3,4,5,6,7,8,10,11,12,13,15,16,
         add_indent(c(2,3,4,5,6,7,8,10,11,12,13,15,16,17,18,19,20,22,23,24))
851<br>852
         852 ####Supplemental Figure 1
853<br>854
854 ## Load package<br>855 library(eulerr)
         library(eulerr)
856
857 ## enter numbers of individuals in interaction of sets
858 fit1 <- euler(c("CDW"=0, "Fenton" = 0, "NICHD"=68986,
859 "CDW&Fenton"=0, "Fenton&NICHD"=3534, "CDW&NICHD"=2866, 
                    "CDW&Fenton&NICHD"=33451))
861 ## plot Euler diagram
862 plot(fit1, quantities = TRUE, legend = TRUE)
863<br>864
864 ####Supplemental Figure 2<br>865 ##Same code as Figure 1 but
         ##Same code as Figure 1 but added one line of code in data preparation
866
867 Prevalence4 <- Prevalence4 %>% filter(BirthNumber == "1")
868<br>869
         869 ####Supplemental Figure 3
870 ##Same code as Figure 2 but added one line of code in data preparation<br>871 Outcome8 <- Outcome8 %>% filter(BirthNumber == "1")
         Outcome8 <- Outcome8 %>% filter(BirthNumber == "1")
872
873 ####Figure 1 Interaction Test
874 LogReg3 <- glm(SGA~ Race + MA + DY + Genetic + Any_Anom + Genetic*Any_Anom, data = 
875 Prevalence4, family = "binomial")<br>876 anova(LogReg3, test='Chisq')
876 anova(LogReg3, test='Chisq')<br>877 summary(LogReg3)
         summary(LogReg3)
878
879 ####Figure 2 Interaction Test
```
- 880 LogReg5 <- glm(CritlllorDeath ~ Antenatal.Steroids + Sex + Race + GA + MVD0.2 + Any\_Anom + DY +
- 881 BW\_Z\_Score + Genetic + Deliv\_Mode + Any\_Anom + Genetic\*Any\_Anom, data = Outcome8,
- 882 family = "binomial")<br>883 anova(LogReg5, tes
- 883 anova(LogReg5, test='Chisq')<br>884 summary(LogReg5)
- summary(LogReg5)
- 885
- 886
- 887